U.S. Markets open in 6 hrs 15 mins

These 4 Healthcare Stocks Are Kicking Off The New Year With A Bang

CORAL GABLES, FL / ACCESSWIRE / January 2, 2019 / With the new year only a few days old, the healthcare sector is already showing signs that this year may prove exciting for the market. Given that the industry is primed to meet the demands and necessities of patients by offering innovative treatment options and improved access to primary care. As experts and professionals in the field have worked on developing technologies to improve quality of treatments available for consumers, the healthcare industry, as a whole, has seen tremendous growth. From data-based approaches and analysis consumer demands/needs, advancements in the sector may catalyze potential opportunities for those looking to healthcare. Premier Health Group (PHGRF) (PHGI), Regional Health Properties, Inc (NYSE: RHE), Genocea Biosciences Inc (NASDAQ: GNCA), and Synergy Pharmaceutical, Inc (NASDAQ: SGYP) are 4 healthcare stocks heating up on Wednesday.

Premier Health Group (PHGRF) (PHGI) has come into the limelight this past year as a result of the Company's dedication to investing in the development of innovative, high tech treatment solutions for patients in the primary care space. Over the course of the past thirty days, Premier has seen a period of bullish trading as its shared climbed over 30% this past month.

Recent reports indicate that the Company currently boasts an ecosystem of over 100,000 active patients in their network, with plans in the works to increase those numbers on a global scale.

Earlier this month, Premier Health Group (PHGRF) (PHGI) announced that, in an effort to advance its overarching strategy to cover all major verticals associated with primary care as well as develop innovative approaches that combine human skill-based expertise with emerging technologies, it had signed a binding LOI to acquire all outstanding securities of Cloud Practice, Inc.

Dr. Essam Hamza, CEO of Premier Health, said, ''We are ecstatic at the opportunity to build on our patient centric technology platform through the integration of Cloud Practice's suite of software solutions. They have a strong team of developers who are just as enthusiastic as we are about the future of healthcare. We believe that this partnership will help facilitate our vision of integrating telemedicine, online booking and other premium services with our electronic medical record (EMR) system.''

For More Information On Premier Health Group, Click Here

Regional Health Properties, Inc (RHE), a self-managed real estate investment company that invest primarily in properties used for senior-living and long-term care, announced early last week that, at their most recent annual meeting of shareholders, the Company's shareholders approved a proposal to amend their Articles of Incorporation to effect a reverse stock split of the Company's common stock at a ratio of between one-for-six and one-for-twelve, as determined by their board of directors.

Per the press release regarding the announcement, the reverse stock split will not reduce the number of shares of common stock currently authorized under their articles of incorporation, although it will reduce the number of shares of common stock by a factor of twelve.

For More Information On Regional Health Properties, Inc, Click Here

Genocea Biosciences, Inc (GNCA), a biopharmaceutical company developing nuanced approaches to cancer immunotherapies, saw its shares jump 25.52% in late-morning trading on Wednesday, potentially riding out momentum gained from its most recent announcement. On Wednesday, the Company announced the dosing of the first patients in its Phase 1/2 a clinical trial testing the safety, immunogenicity, and clinical efficacy of its new cancer vaccine GEN-009.

Tom Davis, M.D., the company's Chief Medical Officer, said, ''Dosing the first patients with our GEN-009 vaccine represents a significant milestone for Genocea. Importantly, our GEN-009 vaccines use our ATLAS™ platform for neoantigen identification. Unlike machine-based approaches that predict neoantigens and only evaluate the patient's tumor, ATLAS also uses each patient's own immune cells not only to identify true neoantigens that already trigger anti-tumor cytokine responses, but also to eliminate 'inhibitory' antigens that are frequently selected for vaccine inclusion by such in silico approaches.''

For More Information on Genocea Biosciences, Inc, Click Here

Synergy Pharmaceuticals, Inc (SGYP) a biopharmaceutical company that is largely focused on developing originative gastrointestinal therapies, announced in early December that it had entered into an agreement with Bausch Health Companies Inc. through which Bausch Health would acquire substantially all of Synergy's assets, including all rights to TRULANCE®, dolcanatide and related intellectual property, for approximately $200 million in cash.

Troy Hamilton, Chief Executive Officer of Synergy, said, ''We have worked diligently to serve our patients, health care professionals and other stakeholders by bringing TRULANCE® to market and developing other GI therapies to address previously unmet needs. Unfortunately, we have now reached a point where our financial challenges are preventing us from taking this important work to the next level."

For More Information On Synergy Pharmaceuticals, Inc, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 (CASH) for & were paid ''500,000'' shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the ''500,000'' shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information Please click here for full disclaimer.

Contact Information:


SOURCE: StockPrice.com